Association between intrauterine device type and risk of perforation and device expulsion: results from the Association of Perforation and Expulsion of Intrauterine Device study.

algorithm copper intrauterine device data linkage electronic health record expulsion free text intrauterine device levonorgestrel intrauterine device natural language processing propensity score overlap weighting uterine perforation

Journal

American journal of obstetrics and gynecology
ISSN: 1097-6868
Titre abrégé: Am J Obstet Gynecol
Pays: United States
ID NLM: 0370476

Informations de publication

Date de publication:
07 2022
Historique:
received: 06 10 2021
revised: 14 03 2022
accepted: 30 03 2022
pubmed: 9 4 2022
medline: 7 7 2022
entrez: 8 4 2022
Statut: ppublish

Résumé

Intrauterine devices, including levonorgestrel-releasing and copper devices, are highly effective long-acting reversible contraceptives. The potential risks associated with intrauterine devices are low and include uterine perforation and device expulsion. This study aimed to evaluate the risk of perforation and expulsion associated with levonorgestrel-releasing devices vs copper devices in clinical practice in the United States. The Association of Perforation and Expulsion of Intrauterine Device study was a retrospective cohort study of women aged ≤50 years with an intrauterine device insertion during 2001 to 2018 and information on intrauterine device type and patient and medical characteristics. Of note, 4 research sites with access to electronic health records contributed data for the study: 3 Kaiser Permanente-integrated healthcare systems (Northern California, Southern California, and Washington) and 1 healthcare system using data from a healthcare information exchange in Indiana (Regenstrief Institute). Perforation was classified as any extension of the device into or through the myometrium. Expulsion was classified as complete (not visible in the uterus or abdomen or patient reported) or partial (any portion in the cervix or malpositioned). We estimated the crude incidence rates and crude cumulative incidence by intrauterine device type. The risks of perforation and expulsion associated with levonorgestrel-releasing intrauterine devices vs copper intrauterine devices were estimated using Cox proportional-hazards regression with propensity score overlap weighting to adjust for confounders. Among 322,898 women included in this analysis, the incidence rates of perforation per 1000 person-years were 1.64 (95% confidence interval, 1.53-1.76) for levonorgestrel-releasing intrauterine devices and 1.27 (95% confidence interval, 1.08-1.48) for copper intrauterine devices; 1-year and 5-year crude cumulative incidence was 0.22% (95% confidence interval, 0.20-0.24) and 0.63% (95% confidence interval, 0.57-0.68) for levonorgestrel-releasing intrauterine devices and 0.16% (95% confidence interval, 0.13-0.20) and 0.55% (95% confidence interval, 0.44-0.68) for copper intrauterine devices, respectively. The incidence rates of expulsion per 1000 person-years were 13.95 (95% confidence interval, 13.63-14.28) for levonorgestrel-releasing intrauterine devices and 14.08 (95% confidence interval, 13.44-14.75) for copper intrauterine devices; 1-year and 5-year crude cumulative incidence was 2.30% (95% confidence interval, 2.24-2.36) and 4.52% (95% confidence interval, 4.40-4.65) for levonorgestrel-releasing intrauterine devices and 2.30% (95% confidence interval, 2.18-2.44) and 4.82 (95% confidence interval, 4.56-5.10) for copper intrauterine devices, respectively. Comparing levonorgestrel-releasing intrauterine devices with copper intrauterine devices, the adjusted hazard ratios were 1.49 (95% confidence intervals, 1.25-1.78) for perforation and 0.69 (95% confidence intervals, 0.65-0.73) for expulsion. After adjusting for potential confounders, levonorgestrel-releasing intrauterine devices were associated with an increased risk of uterine perforation and a decreased risk of expulsion relative to copper intrauterine devices. Given that the absolute numbers of these events are low in both groups, these differences may not be clinically meaningful.

Sections du résumé

BACKGROUND
Intrauterine devices, including levonorgestrel-releasing and copper devices, are highly effective long-acting reversible contraceptives. The potential risks associated with intrauterine devices are low and include uterine perforation and device expulsion.
OBJECTIVE
This study aimed to evaluate the risk of perforation and expulsion associated with levonorgestrel-releasing devices vs copper devices in clinical practice in the United States.
STUDY DESIGN
The Association of Perforation and Expulsion of Intrauterine Device study was a retrospective cohort study of women aged ≤50 years with an intrauterine device insertion during 2001 to 2018 and information on intrauterine device type and patient and medical characteristics. Of note, 4 research sites with access to electronic health records contributed data for the study: 3 Kaiser Permanente-integrated healthcare systems (Northern California, Southern California, and Washington) and 1 healthcare system using data from a healthcare information exchange in Indiana (Regenstrief Institute). Perforation was classified as any extension of the device into or through the myometrium. Expulsion was classified as complete (not visible in the uterus or abdomen or patient reported) or partial (any portion in the cervix or malpositioned). We estimated the crude incidence rates and crude cumulative incidence by intrauterine device type. The risks of perforation and expulsion associated with levonorgestrel-releasing intrauterine devices vs copper intrauterine devices were estimated using Cox proportional-hazards regression with propensity score overlap weighting to adjust for confounders.
RESULTS
Among 322,898 women included in this analysis, the incidence rates of perforation per 1000 person-years were 1.64 (95% confidence interval, 1.53-1.76) for levonorgestrel-releasing intrauterine devices and 1.27 (95% confidence interval, 1.08-1.48) for copper intrauterine devices; 1-year and 5-year crude cumulative incidence was 0.22% (95% confidence interval, 0.20-0.24) and 0.63% (95% confidence interval, 0.57-0.68) for levonorgestrel-releasing intrauterine devices and 0.16% (95% confidence interval, 0.13-0.20) and 0.55% (95% confidence interval, 0.44-0.68) for copper intrauterine devices, respectively. The incidence rates of expulsion per 1000 person-years were 13.95 (95% confidence interval, 13.63-14.28) for levonorgestrel-releasing intrauterine devices and 14.08 (95% confidence interval, 13.44-14.75) for copper intrauterine devices; 1-year and 5-year crude cumulative incidence was 2.30% (95% confidence interval, 2.24-2.36) and 4.52% (95% confidence interval, 4.40-4.65) for levonorgestrel-releasing intrauterine devices and 2.30% (95% confidence interval, 2.18-2.44) and 4.82 (95% confidence interval, 4.56-5.10) for copper intrauterine devices, respectively. Comparing levonorgestrel-releasing intrauterine devices with copper intrauterine devices, the adjusted hazard ratios were 1.49 (95% confidence intervals, 1.25-1.78) for perforation and 0.69 (95% confidence intervals, 0.65-0.73) for expulsion.
CONCLUSION
After adjusting for potential confounders, levonorgestrel-releasing intrauterine devices were associated with an increased risk of uterine perforation and a decreased risk of expulsion relative to copper intrauterine devices. Given that the absolute numbers of these events are low in both groups, these differences may not be clinically meaningful.

Identifiants

pubmed: 35395215
pii: S0002-9378(22)00264-2
doi: 10.1016/j.ajog.2022.03.062
pii:
doi:

Substances chimiques

Contraceptive Agents, Female 0
Levonorgestrel 5W7SIA7YZW

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

57.e1-57.e13

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Jennifer L Gatz (JL)

Regenstrief Institute, Indianapolis, IN. Electronic address: jenngatz@regenstrief.org.

Mary Anne Armstrong (MA)

Division of Research, Kaiser Permanente Northern California, Oakland, CA.

Debbie Postlethwaite (D)

Division of Research, Kaiser Permanente Northern California, Oakland, CA.

Tina Raine-Bennett (T)

Division of Research, Kaiser Permanente Northern California, Oakland, CA; Department of Health Systems Science, Kaiser Permanente Bernard J Tyson School of Medicine, Pasadena, CA.

Giulia Chillemi (G)

Division of Research, Kaiser Permanente Northern California, Oakland, CA.

Amy Alabaster (A)

Division of Research, Kaiser Permanente Northern California, Oakland, CA.

Maqdooda Merchant (M)

Division of Research, Kaiser Permanente Northern California, Oakland, CA.

Susan D Reed (SD)

University of Washington, Seattle, WA.

Laura Ichikawa (L)

Kaiser Permanente Washington Health Research Institute, Seattle, WA.

Darios Getahun (D)

Department of Health Systems Science, Kaiser Permanente Bernard J Tyson School of Medicine, Pasadena, CA; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA.

Michael J Fassett (MJ)

Department of Obstetrics and Gynecology, Kaiser Permanente West Los Angeles Medical Center, Los Angeles, CA; Department of Clinical Science, Kaiser Permanente Bernard J Tyson School of Medicine, Pasadena, CA.

Jiaxiao M Shi (JM)

Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA.

Fagen Xie (F)

Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA.

Vicki Y Chiu (VY)

Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA.

Theresa M Im (TM)

Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA.

Harpreet S Takhar (HS)

Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA.

Jinyi Wang (J)

Research Triangle Institute Health Solutions, Research Triangle Park, NC.

Catherine W Saltus (CW)

Research Triangle Institute Health Solutions, Waltham, MA.

Mary E Ritchey (ME)

Research Triangle Institute Health Solutions, Research Triangle Park, NC.

Alex Asiimwe (A)

Bayer AG, Berlin, Germany.

Federica Pisa (F)

Bayer AG, Berlin, Germany.

Juliane Schoendorf (J)

Bayer AG, Bayer Oy, Espoo, Finland.

Yesmean Wahdan (Y)

Bayer Pharmaceuticals, Whippany, NJ.

Xiaolei Zhou (X)

Research Triangle Institute Health Solutions, Research Triangle Park, NC.

Shannon Hunter (S)

Research Triangle Institute Health Solutions, Research Triangle Park, NC.

Mary S Anthony (MS)

Research Triangle Institute Health Solutions, Research Triangle Park, NC.

Jeffrey F Peipert (JF)

Indiana University School of Medicine, Indianapolis, IN.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH